New drug cocktail targets tough cancers in early trial

NCT ID NCT02215720

Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a combination of two drugs, temsirolimus and cetuximab, in 45 adults with advanced or metastatic solid tumors that had not responded to standard treatments. The goal was to check safety and see if blocking two cancer pathways at once could slow tumor growth. Results are limited to safety and tumor response measurements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temsirolimus and cetuximab
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 45 participants, focused on safety. The combination may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Gustave Roussy

Villejuif, Val de Marne, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.